UNSPSC 51111778: Alemtuzumab

Drug prescribed and approved by the U.S. Food and Drug Administration for the HIV infection treatment in adults and 6-year children. It is always used in combination with other drugs against the HIV. Atazanavir is a type of drug against the HIV protease inhibitor (PI). It works by blocking the protease, an enzyme produced by the HIV. This prevents HIV multiplication and reduces the virus concentration in blood.

UNSPSC 51111778 Alemtuzumab, a Commodity code, shows little relevant recent activity under its nominal scope. The four most recent state and local opportunities tagged to this code involve naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, emergency medical supplies for fire rescue, and generic pharmaceuticals through cooperative purchasing—none of which align with alemtuzumab, a monoclonal antibody immunosuppressant used in hematologic malignancy and autoimmune disease treatment. The mismatch suggests either miscoding at the issuing-body level or that this code does not reliably capture actual procurement of the drug itself in state and local contracting systems.

The geographic spread across the recent-opportunity set includes Florida, Texas, and Minnesota, with one multistate cooperative purchasing vehicle (MMCAP, administered by the Minnesota Department of Administration), but the opportunities represent pharmaceutical supply chain, emergency response supplies, and pharmacy benefit program development rather than a specific drug procurement pattern. Without opportunities that directly solicit alemtuzumab supply or distribution, business development professionals should verify whether this code is actively used in their target jurisdictions and whether procurement officers tag alemtuzumab acquisitions under a different code—or whether state and local agencies procure the drug as part of larger pharmaceutical supply contracts tagged at a broader family or class level rather than at the commodity tier.